Black Diamond Therapeutics Inc
BDTX2.815USD
+0.225+8.69%
交易中 （美東）報價延遲15分鐘
159.54M總市值
31.34本益比TTM
關於 Black Diamond Therapeutics Inc 公司
Black Diamond Therapeutics, Inc. 是一家臨牀階段腫瘤學公司，專注於開發 MasterKey 療法，以解決臨牀驗證靶點中的致癌突變家族。該公司的 MasterKey 療法旨在解決廣泛的基因定義的患者羣體，克服耐藥性，最大限度地減少野生型介導的毒性，並具有腦滲透性以治療中樞神經系統 (CNS) 疾病。該公司正在推進兩個臨牀階段項目：BDTX-1535，一種腦滲透性第四代表皮生長因子受體 (EGFR) MasterKey 抑制劑，針對 EGFR 突變型非小細胞肺癌 (NSCLC) 和膠質母細胞瘤 (GBM)，以及 BDTX-4933，一種腦滲透性 RAF MasterKey 抑制劑，針對實體瘤中的 KRAS、NRAS 和 BRAF 變異。其 BDTX-4876 是一種致癌 FGFR2/3 突變的 MasterKey 抑制劑，與 FGFR1/4 相比具有選擇性。該公司還專注於針對未公開的、已驗證的致癌基因的候選藥物的開發。
公司簡介
公司代碼BDTX
公司名稱Black Diamond Therapeutics Inc
上市日期Jan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
員工數量24
證券類型Ordinary Share
年結日Jan 30
公司地址One Main Street, 14th Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話16174175868
網址https://www.blackdiamondtherapeutics.com/
公司代碼BDTX
上市日期Jan 30, 2020
CEODr. Mark A. Velleca, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
77.15K
+8.69%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-0.03%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
22.52K
+32.52%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
18.29%
Versant Ventures
10.92%
Vestal Point Capital, LP
9.85%
New Enterprise Associates (NEA)
7.82%
Bellevue Asset Management AG
4.81%
Other
48.32%
股東類型
持股股東
佔比
Investment Advisor
36.89%
Venture Capital
18.81%
Investment Advisor/Hedge Fund
18.59%
Hedge Fund
7.37%
Research Firm
1.43%
Individual Investor
0.96%
Bank and Trust
0.18%
Pension Fund
0.02%
Other
15.76%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
254
48.67M
85.58%
-26.49M
2025Q1
261
50.38M
88.73%
-26.95M
2024Q4
246
57.08M
100.88%
-16.52M
2024Q3
250
57.38M
101.59%
-12.76M
2024Q2
242
55.35M
99.47%
-3.18M
2024Q1
244
48.01M
92.96%
-13.90M
2023Q4
235
47.28M
91.68%
-8.00M
2023Q3
256
45.71M
88.75%
-9.85M
2023Q2
259
50.33M
103.17%
+16.38M
2023Q1
277
29.49M
80.76%
-7.91M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
T. Rowe Price Investment Management, Inc.
10.40M
18.29%
-67.48K
-0.64%
Mar 31, 2025
Versant Ventures
6.21M
10.92%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.60M
9.85%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
4.45M
7.82%
--
--
Apr 11, 2025
Bellevue Asset Management AG
2.73M
4.81%
-5.78M
-67.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.36M
4.15%
-47.11K
-1.96%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.14%
-57.11K
-2.37%
Mar 31, 2025
Tang Capital Management, LLC
2.07M
3.64%
--
--
Mar 31, 2025
Millennium Management LLC
1.10M
1.94%
+545.84K
+97.81%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Health Innovation Active ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
Fidelity Enhanced Small Cap ETF
佔比0.04%
iShares Micro-Cap ETF
佔比0.03%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
iShares Health Innovation Active ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
